In the most recent trading session, McKesson (MCK) closed at $603.24, indicating a +0.05% shift from the previous trading day.
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.
McKesson (MCK) closed at $589.95 in the latest trading session, marking a -0.19% move from the prior day.